Latest Derivatives News

Noxopharm Limited reports growing interest in its Sofra technology with new research collaborations and a safe, well-tolerated HERACLES trial of SOF-SKN. The company also secures funding extensions to support ongoing development.

Galileo Mining reports standout gold assays up to 13.7 g/t with significant palladium and platinum at its Norseman project, setting the stage for upcoming RC drilling to test promising bedrock targets.

Gateway Mining Ltd has initiated a large-scale aeromagnetic survey at its Glenburgh South project, while aggressive drilling continues at the flagship Yandal Gold Project, positioning the company for a pivotal exploration phase in 2026.

Tribune Resources reported steady gold output from its East Kundana Joint Venture and promising exploration results in Ghana, alongside a stronger cash position for the September quarter.

Neurizon Therapeutics has secured FDA clearance to resume clinical trials for its lead ALS drug NUZ-001, alongside a $5.2 million capital raise and a key licensing deal with Elanco Animal Health. These developments position the company for a critical growth phase in neurodegenerative disease therapeutics.

L1 Group has completed its merger with Platinum Asset Management, forming a $16.9 billion investment powerhouse focused on stabilising funds under management and unlocking significant cost synergies.

Carlton Investments reported a slight rise in net profit and an 8.7% increase in dividends for FY2025, while its investment portfolio grew nearly 60% over five years despite recent market fluctuations.

Hydrix Limited reports a robust quarter with $3.35 million in sales, a 7% revenue increase, and a strong international client base, while advancing US market ventures.

SOCO Corporation has returned to profitability in FY25, driven by strategic contract wins and client diversification. The company is now focusing on expanding recurring revenues and leveraging AI and cybersecurity capabilities for future growth.

Aeris Resources has announced a maiden open pit Probable Ore Reserve for its Constellation Project in New South Wales, underpinning a 5-to-7-year mine life and leveraging existing Tritton processing infrastructure.

CSL Limited has revised its financial outlook for FY26, citing lower US influenza vaccination rates and government cost controls in China, while postponing the planned demerger of its Seqirus vaccine business and announcing a major cost-saving program.

Syntara Limited reports encouraging Phase 2a results for amsulostat in myelofibrosis, with significant symptom relief and spleen volume reduction sustained over 12 months, alongside new clinical trial initiations and a solid cash position.